CD38 and Miyoshi myopathy: A very recent interim analysis of the phase 3 CASTOR trial also showed that therapeutic anti-CD38 mAb, when combined with bortezomib and dexamethasone, can significantly prolong progressive-free survival (PFS) in patients with early relapsed and/or refractory MM [4].